Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2017, Vol. 37 Issue (2): 88-92    DOI: 10.13523/j.cb.20170213
    
Progress of Stem Cell Therapy in Spinal Cord Injury
CHEN Gang1,2, WU Jun2, ZHU He2, YU Tian-fei1
1. College of Life Science and Agriculture and Forestry, Qiqihar University, Qiqihar 161006, China;
2. State Key Laboratory of Stem Cells and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
Download: HTML   PDF(413KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

The conventional treatment of spinal cord injury (SCI) is decompressive laminectomy within a given time after SCI to prevent the secondary damage. Theoretically, cell replacement therapy can cure SCI, different types of cells can exert therapeutic effects from various aspects including injured spinal cord axon regeneration, neuron reconstruction and remyelinization, and finally promote the functional recovery. The published literatures in recent years which focusing on stem cell therapy in spinal cord injury were reviewed.



Key wordsStem cell      Cell transplantation      Spinal cord injury      Cell therapy     
Received: 05 July 2016      Published: 25 February 2017
ZTFLH:  R394.2  
Cite this article:

CHEN Gang, WU Jun, ZHU He, YU Tian-fei. Progress of Stem Cell Therapy in Spinal Cord Injury. China Biotechnology, 2017, 37(2): 88-92.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170213     OR     https://manu60.magtech.com.cn/biotech/Y2017/V37/I2/88

[1] McDonald J W, Liu X Z, Qu Y, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med, 1999, 5(12):1410-1412.
[2] Salewski R P, Mitchell R A, Shen C, et al. Transplantation of neural stem cells clonally derived from embryonic stem cells promotes recovery after murine spinal cord injury. Stem Cells Dev, 2015, 24(1):36-50.
[3] Lu P, Woodruff G, Wang Y, et al. Long-distance axonal growth from human induced pluripotent stem cells after spinal cord injury. Neuron, 2014, 83(4):789-796.
[4] Iwai H, Shimada H, Nishimura S, et al. Allogeneic neural stem/progenitor cells derived from embryonic stem cells promote functional recovery after transplantation into injured spinal cord of nonhuman primates. Stem Cells Transl Med, 2015, 4(7):708-719.
[5] Nemati S N, Jabbari R, Hajinasrollah M, et al. Transplantation of adult monkey neural stem cells into a contusion spinal cord injury model in Rhesus macaque monkeys. Cell J, 2014, 16(2):117-130.
[6] Watanabe S, Uchida K, Nakajima H, et al. Early transplantation of mesenchymal stem cells after spinal cord injury relieves pain hypersensitivity through suppression of pain-related signaling cascades and reduced inflammatory cell recruitment. Stem Cells, 2015, 33(6):1902-1914.
[7] Ninomiya K, Iwatsuki K, Ohnishi Y, et al. Intranasal delivery of bone marrow stromal cells to spinal cord lesions. J Neurosurg Spine, 2015, 23(1):111-119.
[8] Jarocha D, Milczarek O, Wedrychowicz A, et al. Continuous improvement after multiple mesenchymal stem cell transplantations in a patient with complete spinal cord injury. Cell Transplant, 2015, 24(4):661-672.
[9] Nistor G I, Totoiu M O, Haque N, et al. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia, 2005, 49(3):385-396.
[10] Kim J B, Lee H, Arauzo-Bravo M J, et al. Oct4-induced oligodendrocyte progenitor cells enhance functional recovery in spinal cord injury model. EMBO J, 2015, 34(23):2971-2983.
[11] Sharp J, Frame J, Siegenthaler M, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells, 2010, 28(1):152-163.
[12] Li Y, Gautam A, Yang J, et al. Differentiation of oligodendrocyte progenitor cells from human embryonic stem cells on vitronectin-derived synthetic peptide acrylate surface. Stem Cells Dev, 2013, 22(10):1497-1505.
[13] Chew D J, Zhu L, Delivopoulos E, et al. A microchannel neuroprosthesis for bladder control after spinal cord injury in rat. Sci Transl Med, 2013, 5(210):155.
[14] Walker C L, Wang X, Bullis C, et al. Biphasic bisperoxovanadium administration and Schwann cell transplantation for repair after cervical contusive spinal cord injury. Exp Neurol, 2015, 264:163-172.
[15] Deng L X, Walker C, Xu X M. Schwann cell transplantation and descending propriospinal regeneration after spinal cord injury. Brain Res, 2015, 1619:104-114.
[16] Zhang S Q, Wu M F, Piao Z, et al. Edaravone combined with Schwann cell transplantation may repair spinal cord injury in rats. Neural Regen Res, 2015, 10(2):230-236.
[17] Ghosh M, Tuesta L M, Puentes R, et al. Extensive cell migration, axon regeneration, and improved function with polysialic acid-modified Schwann cells after spinal cord injury. Glia, 2012, 60(6):979-992.
[18] Kanno H, Pressman Y, Moody A, et al. Combination of engineered Schwann cell grafts to secrete neurotrophin and chondroitinase promotes axonal regeneration and locomotion after spinal cord injury. J Neurosci, 2014, 34(5):1838-1855.
[19] Witheford M, Westendorf K, Roskams A J. Olfactory ensheathing cells promote corticospinal axonal outgrowth by a L1 CAM-dependent mechanism. Glia, 2013, 61(11):1873-1889.
[20] Lima C, Escada P, Pratas-Vital J, et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair, 2010, 24(1):10-22.
[21] Kadoya K, Lu P, Nguyen K, et al. Spinal cord reconstitution with homologous neural grafts enables robust corticospinal regeneration. Nat Med, 2016, 22(5):479-487.

[1] QIAN Yu,DING Xiao-yu,LIU Zhi-qiang,YUAN Zeng-qiang. An Efficient Monoclonal Establishment Method of Genetically Modified Human Pluripotent Stem Cells[J]. China Biotechnology, 2021, 41(8): 33-41.
[2] LI Kai-xiu,SI Wei. Progress in the Treatment of Inflammatory Bowel Diseases by Exosomes Derived from Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(7): 66-73.
[3] WANG Yu-xuan,CHEN Ting,ZHANG Yong-liang. Research Progress on the Biological Function of MiR-148[J]. China Biotechnology, 2021, 41(7): 74-80.
[4] ZHAO Jiu-mei,WANG Zhe,LI Xue-ying. Role of Signal Pathways and Related Factors Regulating Cartilage Formation in Bone Differentiation of Bone Marrow Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(10): 62-72.
[5] CHEN Fei,WANG Xiao-bing,XU Zeng-hui,QIAN Qi-jun. Molecular Mechanism and Clinical Research Progress of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus[J]. China Biotechnology, 2020, 40(7): 59-69.
[6] MAO Kai-yun,ZHAO Ruo-chun,WANG Yue,FAN Yue-lei,JIANG Hong-bo. Analysis on the Development Trend of CMO/CDMOS Industry in Global Cell Therapy[J]. China Biotechnology, 2020, 40(6): 106-112.
[7] DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.
[8] YUAN Ya-kun,LIU Guang-yang,LIU Yong-jun,XIE Ya-fang,WU Hao. Comparison of Research and Clinical Transformation on Mesenchymal Stem Cells between China and the US[J]. China Biotechnology, 2020, 40(4): 97-107.
[9] YANG Dan,TIAN Hai-shan,LI Xiao-kun. Research Progress of Fibroblast Growth Factor 5[J]. China Biotechnology, 2020, 40(3): 117-124.
[10] LI Yu,ZHANG Xiao. The Experience and Enlightenment of Cell Therapy Regulation Dual-track System in Japan[J]. China Biotechnology, 2020, 40(1-2): 174-179.
[11] CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.
[12] QIU Dan-dan,LU Cai-xia,DAI Jie-jie. Application of Hepatocyte-like Cells Derived from Induced Pluripotent Stem Cells in HCV Infection Model[J]. China Biotechnology, 2020, 40(11): 67-72.
[13] ZHU Yongzhao,TAO Jin,REN Meng-meng,XIONG Ran,HE Ya-qin,ZHOU Yu,LU Zhen-hui,DU Yong,YANG Zhi-hong. Autophagy Protects Against Apoptosis of Human Placental Mesenchymal Stem Cells of Fetal Origin Induced by Tumor Necrosis Fator-α[J]. China Biotechnology, 2019, 39(9): 62-67.
[14] Yu-sheng OU,Hong-jun ZHENG,Shi ZHONG,Yi LI. TAEST16001:TCR Affinity Enhanced Specific-T-cell Therapy[J]. China Biotechnology, 2019, 39(2): 49-61.
[15] Yue-lei FAN,Jiao LU,Da-ming CHEN,Kai-yun MAO. Strategies for Stem Cell Patent Evaluation and Patent Transfer and Transformation[J]. China Biotechnology, 2019, 39(1): 99-106.